Middle East and Africa Human Fibrin Glue Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Middle East and Africa Human Fibrin Glue Market Segmentation, By Package Form (Liquid, Patch, and Others), Application (Cardiac Surgery, Pulmonary Surgery, Burn Bleeding, Vascular Surgeries, Orthopedic Surgeries, Lacerations of liver and Spleen, Neurosurgery, Plastic Surgery, General Surgery, Wound Management, and others), Distribution Channel (Direct Tender and Retail Sales), End User (Hospitals, Ambulatory Care Centers, Specialty Clinics, and Others), - Industry Trends and Forecast to 2033

Human Fibrin Glue Market Size

• The Middle East and Africa human fibrin glue market size was valued at USD 20.97 Million in 2025and is expected to reach USD 34.96 Million by 2033, at a CAGR of 6.60% during the forecast period
• The market growth is largely fueled by the increasing number of surgical procedures, rising prevalence of trauma and chronic wounds, and growing adoption of advanced hemostatic agents in healthcare settings, leading to greater utilization of biological sealants across hospitals and specialty clinics
• Furthermore, rising demand for effective tissue sealing, rapid wound healing, and blood loss management solutions is establishing human fibrin glue as an essential component in modern surgical and regenerative treatment practices. These converging factors are accelerating the uptake of Human Fibrin Glue solutions, thereby significantly boosting the industry's growth.

Human Fibrin Glue Market Analysis

• Human fibrin glue, used as a biological tissue adhesive and hemostatic agent in surgical procedures, is becoming increasingly vital in modern healthcare settings due to its effectiveness in controlling bleeding, promoting wound healing, and reducing surgical complications across a wide range of medical applications
• The escalating demand for human fibrin glue is primarily fueled by the rising number of surgical procedures worldwide, increasing prevalence of chronic injuries and trauma cases, and growing preference for minimally invasive surgeries and advanced wound care solutions
• The Saudi Arabia Human Fibrin Glue market dominated the Middle East & Africa region with the largest revenue share of 31.7% in 2025, characterized by increasing healthcare investments, expanding hospital infrastructure, and growing adoption of advanced surgical sealants and hemostatic products. The market growth is further supported by the rising number of surgical procedures, improving access to specialized healthcare services, and increasing focus on advanced wound management and minimally invasive surgical techniques across the country
• The U.A.E. is expected to be the fastest growing country in the Human Fibrin Glue market during the forecast period due to rising healthcare expenditure, growing medical tourism industry, rapid adoption of advanced surgical technologies, and increasing awareness regarding effective tissue sealing and wound healing solutions in hospitals and specialty clinics
• The liquid segment dominated the largest market revenue share of 61.4% in 2025, driven by its extensive use in surgical procedures requiring rapid hemostasis and tissue sealing

Report Scope and Human Fibrin Glue Market Segmentation

Human Fibrin Glue Market Trends

“Increasing Adoption of Advanced Surgical Sealants and Hemostatic Technologies”

• A significant and accelerating trend in the Middle East and Africa Human Fibrin Glue market is the growing adoption of advanced surgical sealants and biologic hemostatic agents designed to improve wound closure efficiency, minimize blood loss, and enhance postoperative recovery outcomes
• For instance, healthcare providers are increasingly utilizing human fibrin glue products in cardiovascular surgeries, orthopedic procedures, neurological surgeries, and liver surgeries due to their strong adhesive and hemostatic properties. These products help surgeons achieve rapid tissue sealing while reducing complications associated with conventional sutures and staples
• The integration of advanced biomaterials and improved fibrin-based formulations is enhancing the effectiveness and safety profile of fibrin sealants. Manufacturers are focusing on developing products with improved biocompatibility, faster clot formation, and enhanced tissue adhesion capabilities to support complex surgical procedures
• Furthermore, minimally invasive surgeries are driving the demand for fibrin glue products, as these procedures require precise bleeding control and efficient tissue sealing solutions. The increasing preference for laparoscopic and robotic-assisted surgeries is further accelerating market expansion globally
• The growing emphasis on reducing surgical complications, shortening hospital stays, and improving patient recovery times is encouraging hospitals and surgical centers to adopt advanced fibrin sealant technologies as part of standard surgical protocols
• This trend toward safer, more efficient, and biologically compatible surgical adhesives is reshaping modern surgical practices and is expected to support continued innovation and growth in the Human Fibrin Glue market

Human Fibrin Glue Market Dynamics

Driver

“Rising Number of Surgical Procedures and Growing Demand for Effective Hemostasis Solutions”

• The increasing volume of surgical procedures worldwide, combined with the growing need for effective bleeding management and tissue sealing solutions, is a major driver fueling the growth of the Human Fibrin Glue market
• For instance, the rising prevalence of cardiovascular diseases, traumatic injuries, orthopedic disorders, and chronic medical conditions has significantly increased the number of surgical interventions performed globally, thereby driving demand for fibrin sealants
• Healthcare professionals are increasingly adopting human fibrin glue products because they help reduce intraoperative blood loss, improve surgical precision, and lower the risk of postoperative complications. These advantages are making fibrin glue an important component in modern surgical care
• Furthermore, the growing geriatric population, which is more susceptible to chronic diseases and surgical procedures, is contributing to higher demand for advanced hemostatic products across hospitals and specialty surgical centers
• Increasing healthcare expenditure, expansion of healthcare infrastructure, and ongoing technological advancements in surgical procedures are further supporting market growth. In addition, growing awareness regarding patient safety and faster postoperative recovery is encouraging wider adoption of fibrin-based surgical sealants globally

Restraint/Challenge

“High Product Costs and Risk of Product-Related Complications”

• The high cost associated with human fibrin glue products and advanced surgical sealants remains a significant challenge for broader market adoption, particularly in cost-sensitive healthcare systems and developing regions
• For instance, the production of fibrin glue involves complex plasma-derived manufacturing processes, stringent safety protocols, and extensive regulatory compliance, all of which contribute to elevated product pricing
• In addition, concerns regarding potential product-related complications such as allergic reactions, infection risks, or transmission of blood-borne pathogens may limit adoption in certain healthcare settings despite rigorous screening and purification procedures
• The availability of alternative wound closure methods and conventional hemostatic products, including sutures, staples, and synthetic sealants, also creates competitive pressure within the market. Some healthcare providers may continue using lower-cost alternatives depending on procedural requirements and budget limitations
• Furthermore, strict regulatory approval processes and quality control requirements for plasma-derived products can increase development timelines and operational costs for manufacturers, posing additional market challenges
• Addressing these challenges through improved manufacturing technologies, enhanced product safety measures, cost-effective production strategies, and continued clinical research will be essential for sustaining long-term growth in the Middle East and Africa Human Fibrin Glue market

Human Fibrin Glue Market Scope

The market is segmented on the basis of package form, application, distribution channel, and end user.

• By Package Form

On the basis of package form, the Human Fibrin Glue market is segmented into liquid, patch, and others. The liquid segment dominated the largest market revenue share of 61.4% in 2025, driven by its extensive use in surgical procedures requiring rapid hemostasis and tissue sealing. Surgeons widely prefer liquid fibrin glue because of its ease of application, strong adhesive properties, and ability to conform to irregular wound surfaces. The growing number of cardiovascular, orthopedic, and general surgeries globally has significantly contributed to the demand for liquid formulations. In addition, liquid fibrin glue provides effective bleeding control while reducing surgical complications and operation time. Hospitals increasingly adopt liquid-based fibrin sealants due to their compatibility with minimally invasive surgical procedures and advanced applicator systems. The rising prevalence of chronic diseases requiring surgical intervention has further strengthened market growth. Furthermore, advancements in biologic sealant technologies and increasing healthcare expenditure are supporting broader adoption across developed and emerging healthcare systems. The strong availability of commercially approved products and growing awareness regarding blood loss management continue to sustain segment dominance during the forecast period.

The patch segment is anticipated to witness the fastest CAGR of 20.8% from 2026 to 2033, driven by increasing adoption in complex surgeries and wound management applications. Fibrin patches provide localized hemostatic action with enhanced convenience and reduced preparation time during surgical procedures. Healthcare professionals increasingly prefer patches because they combine sealing and tissue support functions in a single product format. The growing demand for minimally invasive and trauma-related surgeries has accelerated the utilization of fibrin sealant patches. In addition, technological advancements in bioengineered absorbable patches are improving surgical outcomes and patient recovery rates. Rising incidences of burns, traumatic injuries, and postoperative bleeding complications are further contributing to segment expansion. The increasing focus on infection prevention and reduced hospitalization duration is also expected to support strong future demand for fibrin patch products globally.

• By Application

On the basis of application, the Human Fibrin Glue market is segmented into cardiac surgery, pulmonary surgery, burn bleeding, vascular surgeries, orthopedic surgeries, lacerations of liver and spleen, neurosurgery, plastic surgery, general surgery, wound management, and others. The cardiac surgery segment held the largest market revenue share of 29.7% in 2025, driven by the increasing number of cardiovascular procedures and the critical need for effective hemostatic agents during surgery. Human fibrin glue is extensively utilized in cardiac surgeries to reduce blood loss, improve tissue adhesion, and minimize postoperative complications. Surgeons prefer fibrin sealants in cardiovascular procedures because they help shorten surgical duration and enhance patient recovery outcomes. The growing prevalence of coronary artery disease, heart valve disorders, and congenital heart defects has significantly boosted segment demand. In addition, the aging population and rising healthcare investments in advanced cardiac care centers continue to support market growth. Technological advancements in biologic sealants and improved surgical techniques are further strengthening product adoption. Increasing awareness regarding blood conservation strategies and reduced transfusion dependency is expected to maintain segment dominance throughout the forecast period.

The wound management segment is expected to witness the fastest CAGR of 22.1% from 2026 to 2033, driven by rising incidences of chronic wounds, burns, and traumatic injuries globally. Human fibrin glue is increasingly used in wound care because of its ability to accelerate tissue healing and provide effective bleeding control. Healthcare providers are adopting fibrin-based wound management solutions to reduce infection risks and improve healing outcomes in complex injuries. The growing diabetic population and increasing prevalence of pressure ulcers and surgical wounds are significantly supporting segment expansion. In addition, advancements in regenerative medicine and biologic wound care products are driving innovation in fibrin sealant applications. Hospitals and specialty clinics are increasingly integrating fibrin-based therapies into advanced wound care protocols. Rising awareness regarding minimally invasive wound closure techniques and improved patient outcomes is expected to further accelerate future market growth.

• By Distribution Channel

On the basis of distribution channel, the Human Fibrin Glue market is segmented into direct tender and retail sales. The direct tender segment accounted for the largest market revenue share of 68.5% in 2025, driven by the high procurement volume of fibrin glue products by hospitals and large healthcare institutions. Direct tender procurement allows healthcare providers to secure products at competitive pricing while ensuring continuous supply for surgical procedures. Hospitals and government healthcare organizations increasingly prefer direct tender agreements because they streamline procurement processes and improve inventory management efficiency. The growing number of surgical interventions and expanding hospital infrastructure globally have significantly contributed to segment growth. In addition, bulk purchasing agreements with manufacturers help reduce operational costs and ensure consistent product availability in emergency care settings. The increasing adoption of advanced surgical sealants in public healthcare systems further supports strong demand through direct tender channels. Rising healthcare expenditure and government investments in surgical care facilities are expected to sustain the segment’s dominant position during the forecast period.

The retail sales segment is anticipated to witness the fastest CAGR of 18.9% from 2026 to 2033, driven by increasing accessibility of fibrin glue products through private healthcare providers and specialty pharmacies. Retail distribution channels are gaining traction due to the growing expansion of outpatient surgical centers and specialty clinics. Physicians and smaller healthcare facilities increasingly rely on retail procurement for flexible purchasing and immediate product availability. The rising awareness regarding advanced wound care and minimally invasive surgeries has also contributed to higher demand through retail channels. In addition, the expansion of medical supply distributors and e-commerce healthcare platforms is improving market accessibility globally. Increasing private healthcare investments and the growing presence of specialty surgical centers are expected to further strengthen retail segment growth in the coming years.

• By End User

On the basis of end user, the Human Fibrin Glue market is segmented into hospitals, ambulatory care centers, specialty clinics, and others. The hospitals segment dominated the largest market revenue share of 64.2% in 2025, driven by the high volume of surgical procedures performed in hospital settings worldwide. Hospitals are the primary end users of human fibrin glue due to the availability of advanced surgical infrastructure, skilled healthcare professionals, and emergency care facilities. Increasing incidences of cardiovascular diseases, orthopedic conditions, and trauma cases requiring surgical intervention have significantly boosted demand within hospitals. In addition, hospitals increasingly adopt fibrin sealants to improve surgical efficiency, minimize blood loss, and enhance postoperative recovery outcomes. Government investments in healthcare infrastructure and the expansion of multispecialty hospitals are further supporting segment growth. Technological advancements in surgical procedures and rising patient preference for minimally invasive operations continue to strengthen market demand. Furthermore, the growing availability of reimbursement support for surgical treatments in developed economies is expected to maintain hospital segment dominance during the forecast period.

The ambulatory care centers segment is projected to witness the fastest CAGR of 21.3% from 2026 to 2033, driven by the increasing shift toward outpatient surgical procedures and cost-effective healthcare delivery models. Ambulatory care centers are increasingly adopting fibrin glue products due to their ability to support minimally invasive surgeries with shorter recovery times. Patients increasingly prefer ambulatory surgical settings because of reduced hospitalization costs and faster discharge processes. The growing number of same-day surgical procedures and advancements in outpatient surgical technologies are significantly contributing to segment growth. In addition, favorable healthcare policies promoting ambulatory care services are accelerating the adoption of advanced surgical sealants in these facilities. Rising investments in specialized outpatient centers and increasing patient awareness regarding convenient surgical care options are further expected to support strong future market expansion.

Human Fibrin Glue Market Regional Analysis

• The Middle East and Africa human fibrin glue market is projected to expand at a notable CAGR throughout the forecast period, primarily driven by increasing healthcare investments, rising surgical procedure volumes, and growing demand for advanced wound management and hemostatic solutions across healthcare facilities
• Expanding hospital infrastructure, improving access to specialized surgical care, and rising awareness regarding minimally invasive treatment approaches are supporting the adoption of human fibrin glue products across the region
• In addition, the growing focus on enhancing surgical outcomes and reducing post-operative complications is further contributing to market growth in the Middle East and Africa healthcare sector

Saudi Arabia Human Fibrin Glue Market Insight

The Saudi Arabia human fibrin glue market accounted for the largest revenue share of 31.7% in the Middle East & Africa region in 2025, driven by increasing healthcare investments, expanding hospital infrastructure, and growing adoption of advanced surgical sealants and hemostatic products. The rising number of surgical procedures, coupled with improving access to specialized healthcare services, is significantly contributing to market growth in the country. Furthermore, increasing focus on advanced wound management solutions and minimally invasive surgical techniques is supporting the continued expansion of the Human Fibrin Glue market in Saudi Arabia.

U.A.E. Human Fibrin Glue Market Insight

The U.A.E. human fibrin glue market is expected to witness the fastest growth rate in the Middle East & Africa region during the forecast period, fueled by rising healthcare expenditure, growing medical tourism industry, and rapid adoption of advanced surgical technologies. Increasing awareness regarding effective tissue sealing and wound healing solutions, along with expanding utilization of advanced surgical products in hospitals and specialty clinics, is accelerating market growth in the country. In addition, ongoing healthcare infrastructure development and rising demand for high-quality surgical care are further driving the adoption of human fibrin glue products in the U.A.E.

Human Fibrin Glue Market Share

The Human Fibrin Glue industry is primarily led by well-established companies, including:

• Baxter International Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• CSL Limited (Australia)
• Grifols, S.A. (Spain)
• Takeda Pharmaceutical Company Limited (Japan)
• Becton, Dickinson and Company (U.S.)
• Pfizer Inc. (U.S.)
• Sanofi S.A. (France)
• Ethicon, Inc. (U.S.)
• CryoLife, Inc. (U.S.)
• Tissuemed Ltd. (U.K.)
• Integra LifeSciences Holdings Corporation (U.S.)
• Braun Melsungen AG (Germany)
• Hemarus Therapeutics Limited (India)
• Vivostat A/S (Denmark)
• Shanghai RAAS Blood Products Co., Ltd. (China)
• CSL Behring (U.S.)
• Octapharma AG (Switzerland)
• Omrix Biopharmaceuticals Ltd. (Israel)
• Advanced Medical Solutions Group plc (U.K.)

Latest Developments in Middle East and Africa Human Fibrin Glue Market

• In June 2021, Baxter International highlighted expanded clinical utilization of its TISSEEL fibrin sealant across cardiovascular, general, and pediatric surgeries, reinforcing the growing adoption of human fibrin glue products for surgical hemostasis and tissue sealing applications. The development reflected increasing demand for advanced biologic sealants in minimally invasive and complex surgical procedures
• In April 2022, Grifols received U.S. FDA approval for an expanded indication of VISTASEAL fibrin sealant for use as an adjunct to hemostasis in surgical procedures involving mild to moderate bleeding. The approval strengthened the company’s position in the Middle East and Africa human fibrin glue market and broadened the clinical applicability of fibrin sealants in surgical care
• In September 2023, Baxter International emphasized ongoing advancements in fibrin sealant technologies through updated clinical education initiatives comparing TISSEEL and VISTASEAL products for surgical bleeding management. The initiative highlighted growing industry focus on improving efficacy, ease of application, and patient safety in fibrin-based surgical sealants
• In December 2024, Grifols announced updated regulatory approvals and clinical review documentation for VISTASEAL from the U.S. FDA, supporting expanded usage and reinforcing the product’s effectiveness in surgical hemostasis for heparinized patients. The development reflected continued innovation and regulatory progress within the Middle East and Africa human fibrin glue market.
• In September 2025, Baxter International received U.S. FDA approval for updated labeling and expanded indications for ARTISS fibrin sealant, including enhanced usage guidance for skin graft adhesion and tissue flap procedures. The approval also incorporated improvements in preparation instructions and viral safety data, highlighting continued advancements in human fibrin glue products for reconstructive and burn surgeries

SKU-66686